Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biological Heterogeneity of Chondrosarcoma: From (Epi) Genetics through Stemness and Deregulated Signaling to Immunophenotype

15 Mar 2021

Abstract excerpt

Chondrosarcoma (ChS) is a primary malignant bone tumor. Due to its heterogeneity in clinical outcomes and resistance to chemo- and radiotherapies, there is a need to develop new potential therapies and molecular targets of drugs. Many genes and pathways are involved in in ChS progression. The most frequently mutated genes are isocitrate dehydrogenase ½ (IDH1/2), collagen type II alpha 1 chain (COL2A1), and TP53....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Tumor Diagnosis and Treatments
Share to interferon and immune responses
Share to Sarcoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33804155
DOI: 10.3390/cancers13061317

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biological Heterogeneity of Chondrosarcoma: From (Epi) Genetics through Stemness and Deregulated Signaling to ImmunophenotypePMID 33804155Read ↗

Advances in the Molecular Biology of Chondrosarcoma for Drug Discovery and Precision MedicineSemantic proximity Read ↗

Chondrosarcoma: biology, genetics, and epigeneticsSemantic proximity Read ↗

Presence of IDH2 and TP53 mutations significantly reduces survival of patients with chondrosarcoma.Semantic proximity Read ↗

Dedifferentiated Chondrosarcoma: Current Advances and Future Perspectives.Semantic proximity Read ↗

Integrated Immune and Molecular Profiling Identifies Prognostic Subgroups and Therapeutic Targets in Chondrosarcoma.Semantic proximity Read ↗

Epigenetic Abnormalities in ChondrosarcomaSemantic proximity Read ↗

Genomic Characterization of Chondrosarcoma Reveals Potential Therapeutic TargetsSemantic proximity Read ↗

Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targetsSemantic proximity Read ↗

Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes.Semantic proximity Read ↗

Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade ChondrosarcomaSemantic proximity Read ↗

Molecular oncogenesis of chondrosarcoma: impact for targeted treatmentSemantic proximity Read ↗

Distinct IDH1/2-associated Methylation Profile and Enrichment of TP53 and TERT Mutations Distinguish Dedifferentiated Chondrosarcoma from Conventional Chondrosarcoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.